EryPharm
EryPharm developed a mass production process for cultured red blood cells as a transfusion product.
EryPharm developed a mass production process for cultured red blood cells as a transfusion product.
Erypharm is a biotech startup company founded in 2016, based in France. The company has developed a mass production process for cultured red blood cells as a transfusion product. This innovative technology, originated from the research conducted by Dr. Luc Douay and his team at the Paris Sorbonne University, has garnered considerable attention. Erypharm received a significant boost when it secured a €16.38M Seed Round investment on July 19, 2016. The investment came from AGORANOV and Corely. Erypharm aims to revolutionize the biotechnology industry with its groundbreaking approach and has the potential to significantly impact the field of medical research and healthcare. For further information, Erypharm can be reached via their website at http://erypharm.com/contact.html, or directly through Loïc Tron at www.linkedin.com/in/loictron.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | €16.38M | 2 |
|
19 Jul 2016 |
No recent news or press coverage available for EryPharm.
We care about your data, and we'd love to use cookies make your experience better.
